Floatz logo

CEFADROXIL ANHYDROUS

Tobacco Use

Mayo ClinicSmall moleculePhase 4 / ApprovedActive
BB
65/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
50/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Tobacco Use cohort.

Asset / SponsorPhaseRating
Nicotine
Brown University
Phase 4A
Varenicline Tartrate
University of California, San Diego
Phase 4A
Varenicline Tartrate
University of California, San Diego
Phase 4BBB
Naltrexone
Yale University
Phase 4BBB
Varenicline Tartrate
Corporal Michael J. Crescenz VA Medical Center
Phase 4BBB

View all 34 →

Same molecule, other indications

CEFADROXIL ANHYDROUS is also rated in:

periprosthetic joint infectionDormant
BB
Indicative ·
65 / 100
View asset →
methicillin-susceptible staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →
methicillin-resistant staphylococcus aureus infectious diseaseDormant
BB
Indicative ·
65 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →